Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Research indicates that some weight regain is common when treatment stops
The results of our study are subject to several limitations
Among anti-obesity medication (AOM) users, the switch rate is just 2 percent, while type 2 diabetes (T2D) patients show a slightly higher rate at 7 percent, likely due to broader payer coverage for branded diabetes therapies
Hammond, J
Injectable GLP-1-based therapies, including semaglutide and tirzepatide, have demonstrated substantial benefits for weight loss and cardiometabolic risk reduction ( 1 3 ), but real-world uptake has been shaped by factors such as route of administration, access, tolerability, and insurance coverage ( 4 7 )
Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus
